• Traders who were banking on some kind of hugely positive announcement (more consequential than the M402 news) in conjunction with the quarterly results might be inclined to sell today.
• There could be some selling stemming from MNTA’s guidance for continued quarterly losses until Copaxone is approved, although this should not have been a surprise to anyone who follows the company closely.
Market Data 
Markets 
AI
